Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy

ConclusionTargeted therapies, especially those inhibiting PI3K, display promising effects in multiple chordoma cell line and xenograft models. Nevertheless, the limited effects of PI3K, EGFR, and CDK targeting agents in other models reveal the presence of resistance mechanisms, which motivates future research to both identify biomarkers of response and develop combination therapies.

Source: Journal of Neuro-Oncology - February 16, 2020 Category: Cancer & Oncology Source Type: research